[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Universidad Católica San Antonio de Murcia\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":389},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,14,0,[8,44,73,104,131,158,187,214,237,261,290,316,341,366],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100568735","translation-and-validation-of-the-limbs-pain-autonomy-depression-anxiety-and-quality-of-life-scales-in-albanian-100568735",false,"NCT06685094","Translation and Validation of the Limbs, Pain, Autonomy, Depression, Anxiety and Quality of Life Scales in Albanian","Cross-cultural Adaptation, Translation and Validation of the Assessment Scales of the Upper and Lower Limbs, Pain, Autonomy, Depression, Anxiety and Quality of Life for Use in the Albanian-speaking Population","Inclusion Criteria:\n\n* articular and muscular pain\n* back pain\n* presence of rheumatologic symptoms\n* functional misbalance\n* scoliosis\n* musculoskeletal disorders\n\nExclusion Criteria:\n\n* no native albanian language\n* severe trauma to the lumbar spine or hip(s)\n* tumor\n* metabolic disease",true,"ALL","18 Years","80 Years",{"count":21,"type":22},300,"ESTIMATED","OBSERVATIONAL","The cross-cultural adaptation will be performed according to the internationally recommended methodology, using the following guidelines: translation, back-translation; revision by a committee, questionnaire diffusion and data collection and analyzing.\n\nThe psychometric properties will be evaluated by administering the questionnaire to approximately 300 participants. Reliability will be estimated through stability and homogeneity assessment",[26,27,28,29,30],"Musculoskeletal Pain","Autonomy","Healthy","Upper Limb Injury","Lower Limb Injury","RECRUITING","2026-06-02",{"date":34,"type":35},"2026-06-04","ACTUAL",{"date":37,"type":35},"2025-06-30",{"date":39,"type":22},"2027-09-01",{"name":41,"class":42},"Universidad Católica San Antonio de Murcia","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":17,"minAge":52,"maxAge":53,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":43},"100632922","xanthigen-and-its-impact-on-weight-and-metabolic-health-100632922","NCT07519980","Xanthigen and Its Impact on Weight and Metabolic Health","Effects of Xanthigen on Weight Control and Metabolic Variables in Overweight Individuals","XAN","Inclusion Criteria:\n\n* The subject is able and willing to follow the study protocol procedures to sign the informed consent form prior to the evaluations.\n* Participants must be between 20 and 50 years of age at the time of consent.\n* The subject is in good physical and mental health as determined by medical history, physical examination, electrocardiogram, vital signs, biochemistry, and hematology results.\n* Participants must have a BMI between 27 and 29.9 kg\u002Fcm2.\n* Desire to lose weight.\n\nExclusion Criteria:\n\n* Relevant medical history or presence of any medical condition that could interfere with this study, such as a previous diagnosis of diabetes, hypertension, hyperlipidemia, cardiovascular disease, thyroid disease, asthma, arthritis, or inflammatory conditions.\n* Fasting blood sugar levels greater than 125 mg\u002FdL and\u002For total cholesterol levels greater than or equal to 240 mg\u002FdL.\n* Blood pressure levels below 90\u002F140 mm Hg (diastolic\u002Fsystolic).\n* Chronic intake of medications\u002Fdietary supplements with an impact on body weight or body composition or lipid-modifying products (e.g., protein shakes, statins, omega-3 fatty acids, etc.) 2 months prior to selection or during the study.\n* Known allergy\u002Fsensitivity to any of the components of the investigational product.\n* Change in hormonal contraception or any use of hormone replacement therapy (HRT) during or at least 3 months prior to the study (if female).\n* Women of childbearing age who are pregnant or intend to become pregnant during the study period.\n* Use of any dietary supplements (except mineral supplements, e.g., Ca, Mg).\n* Participation in any weight loss intervention or recent change in body weight \\> 4.5 kg during the last 9 months.\n* History and\u002For presence of eating disorders such as bulimia, anorexia nervosa, or binge eating, as determined by the investigator.\n* Consumption of any dietary supplements (except mineral supplements, e.g., Ca, Mg).\n* Participation in any weight loss program or recent change in body weight \\> 4.5 kg during the last 9 months.\n* History and\u002For presence of eating disorders such as bulimia, anorexia nervosa, binge eating, as determined by the investigator.\n* Individuals who currently participate in aerobic exercise more than 4 times per week, or more than 2.5 hours per week.\n* Vegan lifestyle.\n* Current smoker or user of nicotine products or cessation of smoking within 1 year of the screening date.\n* Gastrointestinal diseases\u002Fconditions (colitis ulcers, Crohn's disease, peptic ulcers, celiac disease).","20 Years","50 Years",{"count":55,"type":22},180,"INTERVENTIONAL",[58],"NA","Randomized, controlled, triple-blind clinical trial with three parallel arms based on the product consumed (low-dose experimental product, high-dose experimental product, and placebo product) and conducted at a single center to measure the efficacy of a product (Xanthigen®) on overweight or obesity during 16 weeks of consumption.",[61],"Obesity & Overweight",[63,64],"Obesity","Overweight","2026-05-03",{"date":67,"type":35},"2026-05-07",{"date":69,"type":35},"2026-02-02",{"date":71,"type":22},"2026-09-15",{"name":41,"class":42},{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":56,"phases":83,"briefSummary":84,"conditions":85,"keywords":91,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":43},"100627340","clinical-management-of-cardiovascular-risk-factors-in-adult-patients-a-before-and-after-interventional-study-100627340","NCT07447362","Clinical Management of Cardiovascular Risk Factors in Adult Patients: A Before-and-After Interventional Study","Effect of a Structured Clinical and Pharmacological Management Strategy on Cardiovascular Risk Factors in Adult Patients in Routine Clinical Practice: A Pseudo-Experimental Before-and-After Study","CV-RISK","Inclusion Criteria:\n\n* Age ≥18 years\n* Presence of at least one cardiovascular risk factor (hypertension, diabetes, dyslipidemia, obesity, or smoking)\n* Receiving outpatient clinical follow-up\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Severe clinical instability requiring hospitalization\n* Pregnancy\n* End-stage renal disease or dialysis\n* Inability to complete follow-up visits\n* Refusal to participate",{"count":82,"type":22},220,[58],"This study aims to evaluate cardiovascular risk factors, clinical characteristics, and outcomes in adult patients attending an outpatient cardiology clinic. The research focuses on identifying predictors of adverse cardiovascular events, optimizing risk stratification, and improving preventive strategies in routine clinical practice. Data will be collected from patients receiving standard cardiology care without altering their treatment. The results are expected to contribute to better understanding of cardiovascular risk profiles and to support improvements in clinical decision-making and patient management.",[86,87,88,89,63,64,90],"Cardiovascular Risk Factors","Hypertension","Dyslipidemia","Type 2 Diabetes Mellitus","Tobacco Use",[92,93,94,95],"Cardiovascular prevention","Risk factor control","Medication adherence","Clinical follow-up","2026-02-27",{"date":98,"type":35},"2026-03-03",{"date":100,"type":35},"2024-07-24",{"date":102,"type":22},"2026-10-24",{"name":41,"class":42},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":56,"phases":115,"briefSummary":116,"conditions":117,"keywords":119,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":43},"100625312","effect-of-a-nutritional-product-containing-carob-extract-on-carbohydrate-metabolism-in-glucose-intolerant-subjects-100625312","NCT07420998","Effect of a Nutritional Product Containing Carob Extract on Carbohydrate Metabolism in Glucose-intolerant Subjects","Randomized Clinical Trial on the Effect of a Nutritional Product Containing Carob Extract (NUTIFOOD) on Carbohydrate Metabolism in Glucose-intolerant Subjects","NUTIFOOD","Inclusion Criteria:\n\n* Subjects of both sexes aged 18-65 years.\n* Diagnosis of glucose intolerance according to the American Diabetes Association (at least one of the following criteria):\n* Impaired fasting glucose (100-125 mg\u002Fdl)\n* Impaired glucose tolerance (oral glucose tolerance test with 2-hour plasma glucose between 140-199 mg\u002Fdl)\n* Glycated hemoglobin between 5.7% and 6.4%\n* Body mass index between 20-35 kg\u002Fm².\n* Stable dietary habits: no weight gain or loss greater than 5 kg in the last ten weeks.\n* Volunteers capable of understanding the clinical study and willing to comply with the study procedures and requirements.\n\nExclusion Criteria:\n\n* Use of medications that may interfere with glucose metabolism.\n* Subjects with a history of any type of hepatic or renal disease.\n* Alcohol consumption greater than 20 g\u002Fday.\n* History of allergic hypersensitivity or poor tolerance to any component of the study products.\n* Participation in another clinical trial within the three months prior to the study.\n* Lack of willingness or inability to comply with clinical trial procedures.\n* Pregnant or breastfeeding women.","65 Years",{"count":114,"type":22},30,[58],"Randomized, controlled, double-blind clinical trial with two parallel arms based on the product consumed (experimental product and placebo product) and conducted at a single center, to measure the efficacy of the liquid NUTIFOOD product (nutritional product with carob extract) on carbohydrate metabolism.",[118],"Prediabetes",[120,121,122,118],"Glucose","Insulin","Carob","2026-02-16",{"date":125,"type":35},"2026-02-19",{"date":127,"type":35},"2026-01-26",{"date":129,"type":22},"2026-07",{"name":41,"class":42},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":56,"phases":141,"briefSummary":142,"conditions":143,"keywords":145,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":153,"completionDateStruct":155,"leadSponsor":157,"locationsCount":43},"100623019","healthy-effects-of-adapted-aikido-in-people-with-grip-disfunction-100623019","NCT07391189","Healthy Effects of Adapted Aikido in People With Grip Disfunction","Study on the Health Effects of Adapted Physical Activity From Japanese Martial Arts-Aikido.","AdAikido","Inclusion Criteria:\n\n* Be of legal age.\n* Have no prior knowledge of aikido.\n* Not be practicing other martial arts at the time of inclusion in the study or during the adapted training program.\n* Unilateral dysfunction of the hand and\u002For wrist that prevents or hinders tasks related to gripping (only for case group).\n\nExclusion Criteria:\n\n* Presence of anatomical or functional alterations that could affect the performance of aikido techniques (other than those allowed for the study group).\n* Intellectual disability and\u002For inability to understand the informed con- sent.",{"count":140,"type":22},20,[58],"This study investigates the effects of an adapted aikido exercise program on\n\nthe health of adults with unilateral wrist and\u002For hand dysfunction. The un- derlying assumption is that regular practice of adapted aikido may improve\n\nphysical, psychological, and quality-of-life parameters in this population com- pared with a non-exercising control group.",[144],"Unilateral Handgrip Dysfunction",[146,147,148,149],"Aikido","Handgrip Dysfunction","Adapted Physical Activity","Exercise Therapy","2026-02-12",{"date":152,"type":35},"2026-02-13",{"date":154,"type":35},"2026-01-19",{"date":156,"type":22},"2026-07-15",{"name":41,"class":42},{"id":159,"slug":160,"hasResults":11,"nctId":161,"briefTitle":162,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":56,"phases":168,"briefSummary":169,"conditions":170,"keywords":173,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":43},"100622616","effectiveness-of-genistein-in-mild-cognitive-impairment-100622616","NCT07385937","Effectiveness of Genistein in Mild Cognitive Impairment","Effectiveness of Genistein on the Progression of Cognitive Impairment in Patients With Mild Cognitive Impairment: Controlled Clinical Trial","EXTRAGENIAL","Inclusion Criteria:\n\n* Patient over 50 years of age.\n* Patient diagnosed with mild cognitive impairment (MCI) for Alzheimer's disease (AD) according to the National Institute on Aging and Alzheimer's Association (NIA-AA, 2024) criteria:\n\n  * MMSE scores between 22 and 30 (inclusive; exceptions may be made for subjects with less than 5 years of education).\n  * Evidence of concern about change in cognition, compared to the person's previous level (subjective memory complaint\u002Fimpairment for more than 6 months in the past year and\u002For confirmed by the informant and\u002For physician).\n  * A Clinical Dementia Rating (CDR) score of 0.5 with a memory domain score of 0.5.\n  * Essentially preserved activities of daily living.\n* Evidence of elevated cortical amyloid by positron emission tomography (PET) with F18-flutemetamol. • Patients will be treated pharmaceutically according to the guidelines.\n\nExclusion Criteria:\n\n* Diagnosis of a significant neurological disease other than Alzheimer's disease.\n* Moderate depression as assessed by a Geriatric Depression Scale (GDS-D) score \\>8, or any other serious psychiatric disorder.\n* Taking supplements containing isoflavones.\n* Having a hormone-dependent neoplastic disease.\n* Diagnosis of significant cerebrovascular disease.\n* Having a serious systemic illness that would prevent completion of the study.",{"count":167,"type":22},150,[58],"Randomized, placebo-controlled, double-blind, multicenter clinical trial with two parallel study arms (experimental and placebo) to assess the efficacy of genistein extract consumption over 18 months on cognitive decline in patients with prodromal Alzheimer's disease.",[171,172],"Alzheimer Disease (AD)","Mild Cognitive Impairment (MCI)",[174,175,176,177,178],"Genistein","Dementia","Cognitive impairment","Neuroprotection","Prevention","NOT_YET_RECRUITING",{"date":181,"type":35},"2026-02-17",{"date":183,"type":22},"2026-02",{"date":185,"type":22},"2027-12",{"name":41,"class":42},{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":195,"enrollmentInfo":196,"targetDuration":4,"studyType":56,"phases":198,"briefSummary":199,"conditions":200,"keywords":202,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":43},"100623536","clinical-trial-on-a-natural-compound-to-improve-chronic-inflammation-after-sars-cov-2-infection-100623536","NCT07397910","Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection","Clinical Trial to Analyze the Effectiveness of a Natural Compound on Chronic Immune-mediated Inflammatory Status in Subjects Who Have Had SARS-CoV-2 Infection.","NUTRACOVID","Inclusion Criteria:\n\n* Subjects of both sexes.\n* Subjects over 18 and under 70 years of age who have had a SARS-CoV-2 infection diagnosed by PDIA.\n* Subjects with a history of SARS-CoV-2 infection who, three months after the onset of COVID-19, continue to experience symptoms lasting at least two months that cannot be explained by another cause. These symptoms may be newly developed after initial recovery from an acute COVID-19 episode or persist from the initial illness.\n* No history of sequelae from a severe acute illness.\n\nExclusion Criteria:\n\n* Subjects with an underlying disease that explains the clinical manifestations.\n* Presence of chronic inflammatory diseases.\n* Subjects with acute infections.\n* Evidence of active thromboembolic disorder, defined as those receiving parenteral anticoagulant or thrombolytic treatment.\n* Excessive alcohol consumption.\n* Hypersensitivity or intolerance to any of the components of the study products.\n* Use of any nutraceutical or dietary supplement.\n* Severe or terminal illnesses.\n* Subjects with a body mass index (BMI) over 32.\n* Pregnant or lactating women.","70 Years",{"count":197,"type":22},40,[58],"A controlled, randomized clinical trial is proposed to demonstrate the effectiveness of the experimental product in controlling hepato-pulmonary inflammation and neurovascular encephalic inflammation, which may constitute the etiopathogenic basis of persistent COVID. In addition, an individualized training program will be implemented for each participant in order to improve chronic symptoms and, consequently, their quality of life.",[201],"Long COVID",[203,204,205,206],"LongCOVID","Nutraceutical","Immune-inflammatory state","Exercise",{"date":208,"type":35},"2026-02-09",{"date":210,"type":22},"2026-02-23",{"date":212,"type":22},"2026-08-03",{"name":41,"class":42},{"id":215,"slug":216,"hasResults":11,"nctId":217,"briefTitle":218,"officialTitle":219,"acronym":220,"eligibilityCriteria":221,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":222,"targetDuration":4,"studyType":56,"phases":224,"briefSummary":225,"conditions":226,"keywords":228,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":230,"lastUpdatePostDateStruct":231,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":43},"100622154","evaluating-a-liquid-extract-of-carob-to-improve-blood-sugar-in-people-with-prediabetes-100622154","NCT07379931","Evaluating a Liquid Extract of Carob to Improve Blood Sugar in People With Prediabetes","Randomized Clinical Trial to Analyze the Efficacy of a Liquid Carob Extract on the Glucose Metabolism of Subjects With Prediabetes.","GLIA","Inclusion Criteria:\n\n* Subjects of both sexes aged between 18 and 65.\n* Diagnosis of prediabetes according to the American Diabetes Association (at least one of the following criteria):\n* Impaired fasting glucose (100-125 mg\u002FdL)\n* Glucose intolerance (oral glucose tolerance test with blood glucose between 140-199 mg\u002FdL after 2 hours).\n* Glycated hemoglobin between 5.7 and 6.4%\n* Subjects with a body mass index between 20-35 kg\u002Fm2.\n* Stable eating habits: no weight gain or loss of more than 5 kg in the last ten weeks.\n* Volunteers capable of understanding the clinical study and willing to comply with the study procedures and requirements.\n\nExclusion Criteria:\n\n* Use of medications that may interfere with glucose metabolism.\n* Subjects with a history of any type of liver or kidney disease.\n* Alcohol consumption greater than 20 g\u002Fday.\n* History of allergic hypersensitivity or poor tolerance to any component of the products under study.\n* Participation in another clinical trial in the three months prior to the study.\n* Unwillingness or inability to comply with clinical trial procedures.\n* Pregnant or breastfeeding women.",{"count":223,"type":22},70,[58],"This study evaluates whether a liquid carob extract can improve blood glucose levels in individuals with prediabetes. Participants are selected according to predefined health criteria and randomly assigned to two groups: one group receives the carob extract and the other receives an inert liquid (placebo). Blood samples are collected and glucose-related parameters are measured throughout the study to assess changes over time. The objective is to determine whether this extract may contribute to better glycemic control and help prevent progression to diabetes.",[227],"Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)",[118,120,122,229],"Placebo","2026-01-23",{"date":69,"type":35},{"date":233,"type":22},"2026-01-01",{"date":235,"type":22},"2026-04-30",{"name":41,"class":42},{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":241,"acronym":242,"eligibilityCriteria":243,"healthyVolunteers":16,"sex":17,"minAge":53,"maxAge":19,"enrollmentInfo":244,"targetDuration":246,"studyType":23,"phases":4,"briefSummary":247,"conditions":248,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":258,"leadSponsor":260,"locationsCount":43},"100580188","validity---reliability-of-berg-balance-scale-in-albanian-population-100580188","NCT06834048","Validity - Reliability of Berg Balance Scale in Albanian Population","BERGA","Inclusion Criteria:\n\n* Postural pain\n* muscular contractions\n\nExclusion Criteria:\n\n* mixed fractures\n* trauma\n* luxation\n* tumor",{"count":245,"type":22},200,"7 Days","Cross-cultural adaptation, validity and Reliability of Berg Balance Scale in Albanian population",[249,250,251,252],"Balance Assessment","Balance Control in Elderly","Balance Changes","Geriatric Assessment","2025-11-15",{"date":255,"type":35},"2025-11-19",{"date":257,"type":35},"2025-01-17",{"date":259,"type":22},"2026-01-30",{"name":41,"class":42},{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":266,"acronym":267,"eligibilityCriteria":268,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":112,"enrollmentInfo":269,"targetDuration":4,"studyType":56,"phases":271,"briefSummary":272,"conditions":273,"keywords":275,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":282,"lastUpdatePostDateStruct":283,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":43},"100597725","effect-of-a-probiotic-supplement-on-gut-microbiota-and-glycemic-control-in-patients-with-type-1-diabetes-prodiab-100597725","NCT07062224","Effect of a Probiotic Supplement on Gut Microbiota and Glycemic Control in Patients With Type 1 Diabetes (PRODIAB)","Impact of a Probiotic Supplement on Gut Microbiota and Glycemic Control in Patients With Type 1 Diabetes Mellitus: A Randomized Double-Blind Clinical Trial","PRODIAB","Inclusion Criteria:\n\n* Age between 18 and 65 years.\n* Ability to understand and sign the informed consent form.\n* For the patient group: diagnosis of type 1 diabetes with at least 1 year of disease progression.\n* For the control group: healthy individuals without a diagnosis of diabetes or other metabolic disorders.\n* No use of antibiotics, probiotics, or prebiotics during the 4 weeks prior to the study start.\n* Willingness to comply with the study protocol and attend scheduled visits.\n\nExclusion Criteria:\n\n* Current use of probiotics, prebiotics, or antibiotics.\n* Chronic gastrointestinal diseases (e.g., inflammatory bowel disease, irritable bowel syndrome).\n* Pregnancy or breastfeeding.\n* Participation in another clinical trial within the past 3 months.\n* Immunosuppressive diseases, active cancer, or treatment with immunosuppressants.\n* Known allergy or intolerance to any component of the supplement or placebo.\n* Excessive alcohol or drug use.",{"count":270,"type":22},80,[58],"This randomized, double-blind clinical trial aims to evaluate the effect of a probiotic supplement on gut microbiota composition and glycemic control in adults with type 1 diabetes mellitus. A secondary comparison will be made with a healthy control group. Participants will be assigned to receive either a probiotic or a placebo for 98 days. Stool samples and metabolic parameters will be collected at baseline and after the intervention period. The study seeks to better understand how modulation of the intestinal microbiota may influence glucose regulation in people with type 1 diabetes.",[274],"Diabete Type 1",[276,277,278,279,280,281],"Gut microbiota","Probiotic supplement","Zonulin","Calprotectin","Type 1 Diabetes","Glycemic Control","2025-07-02",{"date":284,"type":35},"2025-07-14",{"date":286,"type":22},"2025-09",{"date":288,"type":22},"2025-12",{"name":41,"class":42},{"id":291,"slug":292,"hasResults":11,"nctId":293,"briefTitle":294,"officialTitle":295,"acronym":4,"eligibilityCriteria":296,"healthyVolunteers":16,"sex":297,"minAge":18,"maxAge":112,"enrollmentInfo":298,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":300,"conditions":301,"keywords":303,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":43},"100589906","predictors-of-physical-activity-in-adult-patients-with-hemophilic-arthropathy-100589906","NCT06960499","Predictors of Physical Activity in Adult Patients With Hemophilic Arthropathy","Predictors of Physical Activity in Adult Patients With Hemophilic Arthropathy. A Multicenter Cross-sectional Cohort Study","Inclusion Criteria:\n\n* Patients with hemophilia A or B\n* Over the age of majority\n* With a medical diagnosis of severe phenotype of the disease\n* With a medical diagnosis of hemophilic arthropathy in the lower limbs\n* Under on-demand or prophylactic drug treatment.\n\nExclusion Criteria:\n\n* Patients who require technical aids for walking\n* Patients who are dependent for activities of daily living\n* Patients over the age of 60\n* Patients with cognitive impairments that prevent them from understanding the questionnaires","MALE",{"count":299,"type":22},88,"Introduction. The development of hemophilic arthropathy causes degenerative joint damage that leads to functional impairment, limiting physical activity and causing disability in patients with hemophilia.\n\nObjectives. i) To assess the level of physical activity in patients with hemophilia; ii) To identify the best predictive model for physical activity in adult patients with hemophilic arthropathy.\n\nMaterial and method. Multicenter cross-sectional cohort study. Eighty-eight patients will be recruited. The dependent variable will be physical activity (International Physical Activity Questionnaire). Secondary variables will be kinesiophobia (Tampa Kinesiophobia Scale), functionality (Functional Independence Scale in Hemophilia), pain intensity, and clinical, anthropometric, and sociodemographic variables.",[302],"Hemophilia",[302,304,305,306,307],"Physical activity","Kinesiophobia","Functionality","Joint pain","2025-04-28",{"date":310,"type":35},"2025-05-07",{"date":312,"type":22},"2025-05-04",{"date":314,"type":22},"2025-06-20",{"name":41,"class":42},{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":17,"minAge":52,"maxAge":112,"enrollmentInfo":323,"targetDuration":325,"studyType":23,"phases":4,"briefSummary":326,"conditions":327,"keywords":329,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":43},"100586823","functionality-of-lower-limbs-in-patients-who-have-undergone-knee-meniscectomy-100586823","NCT06920394","Functionality of Lower Limbs in Patients Who Have Undergone Knee Meniscectomy","Functionality of Lower Limbs in Patients Who Have Undergone Knee Meniscectomy. A Multicenter Ambispective Cohort Study","Inclusion Criteria:\n\n* Persons aged 20 to 65\n* Of both sexes\n* With previous meniscectomy surgery in one of the two knees in the last 5 years\n* Who sign the informed consent document.\n\nExclusion Criteria:\n\n* Patients who require technical aids for walking\n* Dependent patients for carrying out activities of daily living\n* Patients over 65 years of age\n* Patients with cognitive impairments that prevent understanding of tests and evaluations",{"count":324,"type":22},89,"1 Day","Introduction. Meniscal lesions are common and are associated with the development of osteoarthritis of the knee. Work activities that cause mechanical stress can lead to acute or chronic injuries. The surgical treatment for this injury is meniscectomy. Physiotherapy is a widely accepted first-line treatment for patients with meniscus tears.\n\nObjective. To assess the clinical and functional status of patients who have undergone meniscus surgery with and without post-surgical physiotherapy.\n\nMaterial and method. Multicenter ambispective cohort study. 89 patients who have undergone meniscectomy will be recruited. The primary variable of the study will be functionality (Time Up \\& Go), with the prescription of a post-surgical physiotherapy treatment being the dependent variable. The secondary variables, estimated as modifying or confounding, will be range of motion (goniometry), pain intensity (visual analog scale) and kinesiophobia (Tampa scale).",[328],"Meniscectomy Sequelae",[330,306,331,332,305],"Knee meniscectomy","Range of movement","Pain intensity","2025-04-07",{"date":335,"type":35},"2025-04-09",{"date":337,"type":22},"2025-04-05",{"date":339,"type":22},"2025-05-20",{"name":41,"class":42},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":16,"sex":297,"minAge":18,"maxAge":348,"enrollmentInfo":349,"targetDuration":325,"studyType":23,"phases":4,"briefSummary":350,"conditions":351,"keywords":353,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":359,"startDateStruct":361,"completionDateStruct":363,"leadSponsor":365,"locationsCount":4},"100587456","anxiety-in-non-professional-football-players-with-recurrent-hamstring-injuries-100587456","NCT06928623","Anxiety in Non-professional Football Players With Recurrent Hamstring Injuries.","Anxiety in Non-professional Football Players With Recurrent Hamstring Injuries. An Ambispective Cohort Study.","Inclusion Criteria:\n\n* Male athletes aged 18 to 19\n* Registered in the Division of Honor category of the Region of Murcia\n* Who are university students\n* With previous hamstring injuries in the last 12 months.\n\nExclusion Criteria:\n\n* Athletes with an injury, muscular or not, at the time of the study\n* Athletes in their first year as registered soccer players.","19 Years",{"count":299,"type":22},"Introduction. Faced with the risk of injury relapse, and as athletes train and compete, they generate anxiety that limits their ability to push themselves to the maximum, influencing their performance.\n\nObjectives. i) To identify the state and trait anxiety of non-professional athletes with previous hamstring injuries; ii) To evaluate the main prognostic factors of anxiety in these athletes; and iii) To analyze the best predictive model of anxiety in soccer players with previous hamstring injuries.\n\nMaterial and method. Ambispective cross-sectional cohort study. 88 players will be recruited. The primary variable of the study will be anxiety (State-Trait Anxiety Inventory), with the number of recurrences of the study injury being the dependent variable. The secondary variables, estimated as modifying or confounding, will be the main sociodemographic variables (age, type of school\u002Fwork activity), clinical (number of hamstring injuries, number of relapses of injury in the same location, duration of injury in weeks, date of last injury), sports (weekly training load, seasons competing, regular starting line-up) and anthropometric (weight).",[352],"Football Player",[354,355,356,357,358],"Football players","Anxiety","Hamstring muscles","Recurrence of injury","Physiotherapy",{"date":360,"type":35},"2025-04-15",{"date":362,"type":22},"2025-04-10",{"date":364,"type":22},"2025-05-25",{"name":41,"class":42},{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":371,"acronym":372,"eligibilityCriteria":373,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":374,"targetDuration":246,"studyType":23,"phases":4,"briefSummary":375,"conditions":376,"keywords":4,"overallStatus":179,"whyStopped":4,"lastUpdateSubmitDate":381,"lastUpdatePostDateStruct":382,"startDateStruct":384,"completionDateStruct":386,"leadSponsor":388,"locationsCount":4},"100580255","upper-limb-functional-index-100580255","NCT06834919","Upper Limb Functional Index","Translation, Cross-Cultural Adaptation, Validity and Reliability of Upper Limb Functional Index in Albanian Population","ULFI-A","Inclusion Criteria:\n\n* shoulder pain\n* arm pain\n* myofascial pain\n* muscular pain\n* trigger points\n* arthritis\n\nExclusion Criteria:\n\n* tumor\n* metabolic disease\n* neurologic conditions",{"count":245,"type":22},"To translate and validate the Upper Limb Functional Index into Albanian for use in the Albanian-speaking population.",[377,378,379,380],"Upper Limb Function","Upper Limb Pain","Upper Limb; Injury, Superficial, Multiple","Upper Limb Rehabilitation","2025-02-13",{"date":383,"type":35},"2025-02-19",{"date":385,"type":22},"2025-02-18",{"date":387,"type":22},"2025-03-15",{"name":41,"class":42},""]